Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 02 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Enzalutamide Tablets in two dosages. These tablets are indicated for treating specific types of prostate cancer and will be manufactured at Zydus's facility in Ahmedabad. The press release highlights that the annual sales for Enzalutamide Tablets in the United States were significant, indicating a strong market potential.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases